ENVAD-HF: Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
Study Details
Study Description
Brief Summary
The primary objective of this study is to assess the safety and tolerability of sacubitril/valsartan compared with standard of care used for treating BP in patients that have been implanted with the Heart Mate 3 LVAD (events of special interest - all cause death, right ventricular failure, bleeding events, deterioration in renal function, hyperkalemia, symptomatic hypotension).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: sacubitril/valsartan
|
Drug: Sacubitril-Valsartan
Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
|
| Active Comparator: Standard of care Standard of care for treating blood pressure per center protocols |
Drug: Standard of care
standard of care used for treating BP
|
Outcome Measures
Primary Outcome Measures
- Freedom from all-cause death, deterioration in renal function (reaching end-stage renal disease (ESRD), renal death or 50% decline in eGFR), hyperkalemia or symptomatic hypotension [3 months]
End-stage renal disease defined as one of the following: Initiation of dialysis (e.g., hemodialysis, peritoneal dialysis, or continuous venovenous hemodialysis), continuing for ≥ 20 days without known recovery of renal function Initiation of dialysis with death before 30 days (excludes dialysis events associated with acute kidney injury with death before 30 days) A drop in eGFR from baseline (randomization, i.e. Visit 101) to a value <15 mL/min/1.73m2 on two consecutive measurements separated by≥ 20 days Occurrence of kidney transplantation 50% sustained decline in eGFR: 50% decline from baseline (Randomization, Visit 101) as determined by 2 consecutive post-baseline measurements separated by ≥ 20 days Hyperkalemia: serum potassium ≥6.0 mmol/L [mEq/L]) Hypotension: symptomatic reduction in blood pressure requiring withdrawal of study medication or any BP lowering medication
Secondary Outcome Measures
- Change in NT-proBNP from enrolment to 8 weeks [8 weeks]
- Change in Burden of hemocompatibility (hemocompatibility score) [3 months, 12 months]
- Number of RV failure events [3 months, 12 months]
- Time to first unplanned hospitalisation [3 months, 12 months]
- Number of unplanned hospitalizations [3 months, 12 months]
- Change in blood-pressure lowering medications [3 months, 12 months]
- Change in eGFR values [3 months, 12 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent must be obtained before any assessment is performed.
-
≥18 years of age, male or female
-
Recently implanted HeartMate 3 LVAD recipients, in stable condition and deemed ready for discharge or chronic, stable, ambulatory HeartMate 3 LVAD carriers implanted within 1 year prior to enrolment
-
Current acute decompensated HF (including right ventricular failure) requiring therapy with intravenous diuretics or vasodilators and/or inotropic drugs within the past 48 hours
-
History of hypersensitivity to sacubitril/valsartan or to drugs of similar chemical classes, patients with a known history of angioedema 3. Patients with mean blood pressure ≤75 mmHg (systolic blood pressure i.e. Doppler opening blood pressure ≤90 mmHg in those pulsatile and measured by Doppler method) or symptomatic hypotension 4. eGFR < 30 mL/min/1.73m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at Visit 1 5. Patients with serum potassium >5.4 mmol/L (mEq/L) at Visit 1 6. Hemodynamically unstable patients or those with ongoing MCS other than LVAD or those with planned biventricular support 7. Hemodynamically significant aortic insufficiency in the opinion of the investigator 8. Irreversible end-organ dysfunction 9. Previous sacubitril/valsartan use while on LVAD support 10. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major CV surgery, percutaneous coronary intervention (PCI) or carotid angioplasty within 30 days prior to enrolment 11. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular rate >110 bpm at enrolment 12. Any surgical or medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study 13. Active infection with hemodynamic compromise 14. hemoglobin (Hgb) <8 g/dl 15. body mass index (BMI) > 45 kg/m2 16. Congenital heart disease 17. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention within the 6 months after enrolment 18. Evidence of hepatic disease as determined by any one of the following: SGOT (AST) or SGPT (ALT) values exceeding 3x ULN, bilirubin >1.5 mg/dl at Visit 1 19. Pregnant or nursing (lactating) women and women of child-bearing potential unless they are using highly effective methods of contraception
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital Centre Zagreb | Zagreb | Croatia | 10000 | |
| 2 | University Hospital Dubrava | Zagreb | Croatia | 10000 | |
| 3 | Erasmus Medical Centre | Rotterdam | Netherlands | 3015 GD |
Sponsors and Collaborators
- University of Zagreb
Investigators
- Principal Investigator: Maja Cikes, MD, PhD, University of Zagreb School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ENVAD-HF